To our knowledge, this is the first report of a mechanism of resistance of abiraterone treatment attributed to miRNA regulation in controlling the expression of OATP1B3, an androgen transporter that has been implicated in driving the resistance to ADT through the mechanism of increasing uptake of residual androgens into prostate tumors. Here, SLCO1B3 is linked to prostate neoplasm.